UBS analyst Joshua Spector lowered the firm’s price target on Xylem (XYL) to $152 from $155 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL:
- Xylem price target lowered to $160 from $165 at Oppenheimer
- Xylem assumed with a Hold at Jefferies
- Xylem Authorizes New $1.5 Billion Share Repurchase Program
- Xylem authorizes up to $1.5B share buyback program
- Balancing Near-Term Execution Risks and Long-Term Portfolio Upside: Why Xylem Remains a Hold